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Abstract 
Purpose: To investigate the efficacy of Plasma Rich in Growth Factors (PRGF)® for the 
treatment of alveolar osteitis compared to a positive control Alvogyl®.  
Methods: This single centre, single blind, randomised, two treatment, parallel study was 
conducted in a UK dental hospital. All healthy adults who presented with alveolar osteitis 
following tooth extraction over a 3 month period were invited to participate. Each socket was 
randomised and treated with one of two treatment modalities, a test treatment PRGF® or a 
positive control Alvogyl®. Following treatment, patients were reviewed at 3 and 7 days by a 
second clinician blinded to the treatment given. Outcome measures included pain, exposed 
bone, inflammation, halitosis, dysgeusia and quality of life assessment. 
Results: 38 patients with data from 44 sockets, 22 in the PRGF® group and 22 in the 
Alvogyl® group, were analysed. The PRGF® group demonstrated significantly faster bone 
coverage as well as significantly reduced inflammation and halitosis (p<0.05) compared to 
the control group receiving Alvogyl®. There was no significant difference for pain, quality of 
life measures or dysgeusia between the groups. 
Conclusion: PRGF® predictably treated alveolar osteitis following tooth extraction 
compared to the conventional standard treatment of Alvogyl® which has been used for many 
years. PRGF could be considered as an alternative treatment for alveolar osteitis, and indeed 
appears to have significant advantages over Alvogel®.  
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Introduction 
Alveolar osteitis (AO) is a common, painful postoperative complication that can follow tooth 
extraction. Although it is a self-limiting condition, symptoms can last up to 28 days,1 
therefore following diagnosis immediate treatment should be provided in order to expedite 
resolution of the condition and improve quality of life during the healing period. 
AO is described as being postoperative pain originating from the extraction socket, which 
peaks at around 1-3 days following tooth extraction and is associated with partial or total loss 
of the blood clot from the socket, with or without halitosis.2 The incidence varies from 1-5% 
for routine dental extractions to around 30% for third molar extractions depending on the 
degree of tissue trauma caused by tooth extraction,3 with smoking and poor oral hygiene 
being purported risk factors.4 Patients with AO usually seek emergency treatment soon after 
extraction with almost all presenting within a week complaining of severe pain, halitosis and 
dysgeusia (bad taste).2 Treatment, involves some or all of the following: anaesthesia of the 
socket, debridement, irrigation and placement of a dressing with or without sutures, and 
evidence shows that patients tend to require multiple appointments before symptoms 
subside.5  The obtundant dressing Alvogyl® (Septodont – Maidstone, Kent, UK), is 
commonly used to treat AO,6 cases being managed in a similar manner since the 1960s.  
Within the National UK Clinical Guidelines for the management of AO provided by the 
Royal College of Surgeons England 1997, which were reviewed in 2003, the use of an 
obtundant dressing to pack the socket is advised.4 The majority of AO cases worldwide are 
treated with the obtundant dressing Alvogyl® (Septodont – Maidstone, Kent, UK), with 
active ingredients of eugenol, iodoform and butambem.6 It is used on a short term basis (up to 
9 days) and has been shown to reduce post-operative pain compared to no treatment 
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controls.7 However, the presence of Alvogyl® in a healing socket has also been shown to 
cause a foreign body reaction, delayed healing and prolonged pain (14 days).8  
Blood derived platelet-rich concentrates are now used widely in dentistry and medicine for 
tissue regeneration.9, 10 Plasma Rich in Growth Factors Endoret® (PRGF®) (Biotechnology 
Institute, San Antonio, Spain) is a leukocyte-free platelet concentrate which has been shown 
to have tissue regenerating11, 12 and antimicrobial capabilities.13, 14 It is used in a wide range 
of oral surgery procedures to enhance postoperative healing, for example, following implant 
placement and healing of the maxillary sinus membrane.15, 16, 17, 18, 19 It has also recently been 
shown that the occurrence of AO following third molar extraction was reduced in patients 
treated with PRGF® at the time of surgery as compared to a placebo, and further that pain 
and healing times were also reduced.20 
To date only one small study has investigated PRGF® soaked onto Gelfoam® (Pfizer Ltd., 
Tadworth, Surrey, United Kingdom) for the management of AO, with faster healing times 
reported compared to zinc oxide eugenol.21 However, Gelfoam® itself has been shown to 
delay socket healing compared to no treatment controls.22 Furthermore, Gelfoam® has shown 
to increase the incidence of AO compared to no treatment controls when placed in healing 
extraction sockets.23 The effect of Gelfoam® on the efficacy of PRGF® for the treatment of 
AO is not known, but it is likely to have influenced the outcomes of the study by Pal et al.21 
Furthermore, the outcome measures in the study by Pal et al.21 only included pain and speed 
of healing, other important outcomes for AO such as exposed bone, halitosis, dysgeusia and 
quality of life outcomes were not reported. 
The ongoing and unpleasant symptoms along with the repeated need to attend for emergency 
appointments can impact considerably on the quality of life of patients suffering with AO. 
Furthermore, the time and cost implications of repeat emergency appointments can place 
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considerable burden on already busy dental services. It is therefore important to investigate 
other treatment modalities, to improve care and faster healing times. 
This aim of this study was to investigate the efficacy of PRGF® for the treatment of alveolar 
osteitis (AO) in patients following tooth extraction as compared to the efficacy of Alvogyl®, 
the dressing most frequently used for this purpose,6 using the outcome measures of pain, 
exposed bone, inflammation, halitosis, dysgeusia and quality of life measures. 
Methods 
Trial Design 
The study was a single centre, single blind, randomised, two treatment, parallel study in 
patients requiring treatment for AO following a recent dental extraction. 
Participants 
Eligible participants were adults aged 18 years or over being diagnosed with AO following 
tooth extraction by dental clinicians in the Oral surgery Department of the Dental Hospital. 
All patients attending the hospital with AO over a 3 month period were asked to participate in 
the study. AO diagnosis was based on patients having pain and exposed bone, if either of 
these parameters were missing patients were not accepted onto the study. Potential 
participants were provided with an information sheet about the study and those who agreed to 
take part gave written consent. Patients who gave consent were assessed for eligibility, 
exclusion criteria included breast-feeding, bleeding disorders, immunocompromised patients, 
current or recurrent disease/dental pathology that could affect the assessments, severe or 
unstable physical or psychiatric illness, allergy/intolerance to study materials and a recent 
history of alcohol or substance abuse.  
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Details regarding the patient and the tooth extraction were recorded. These details included 
smoking status, date of extraction, date of the onset of AO symptoms, reason for tooth 
extraction, setting of tooth extraction (general dental practice/hospital), method of 
anaesthesia during tooth extraction and complexity of extraction. Complexity of extraction 
was classified as: 1) simple forceps extraction, no bone removal required; 2) forceps 
extraction with minor bone removal/tooth division or 3) complex extraction with flap raised + 
bone removal required. Periodontal status was also recorded using the Basic Periodontal 
Examination (BPE) with a World Health Organisation (WHO) probe. If more than one 3 was 
scored or a 4 in any sextant was recorded, the patient was regarded as having active 
periodontitis. All eligibility and baseline assessments were conducted by a qualified study 
dentist. 
 
Study Setting 
The study was undertaken at a UK Dental Hospital and ethical approval was awarded by the 
NHS Research Ethics Committee South West – Exeter (ref 14/SW/1101), and all participants 
gave informed consent in writing. The study was registered on the ISRCTN registry 
(ISRCTN31193447) and conducted to Good Clinical Practice Guidelines (Medical Research 
Council 1998) following the guidelines from the declaration of Helsinki. 
Interventions 
Eligible patients were randomised to receive either the positive control Alvogyl® or the test 
treatment PRGF® following a predetermined, computer generated, block randomisation 
schedule with the unit being the socket. Randomization numbers were assigned by study staff 
at the study site in ascending numerical order as subjects were determined to be fully eligible 
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to participate in the study. In all cases treatment involved socket debridment, irrigation and 
dressing placement under local anaesthetic followed by suturing, using simple interrupted or 
horizontal mattress 4.0 silk sutures depending on the defect, to help retain the dressing. This 
treatment regime refected the Royal College of Surgeons and local hospital guidelines with 
minimal suturing to ensure study products were not lost from treatment sites. No antibiotics 
were prescribed for any study participant. All initial treatment was conducted by the lead 
clinician, a qualified dentist. Where the defect was randomised to receive the use of 
Alvogyl®, the socket was irrigated with sterile saline and packed with approximately 0.20 g 
of Alvogyl® to fill the defect as per the manufacturer’s instructions.  For patients who were 
randomised to receive PRGF®, four 9ml tubes of venous blood containing 3.8% sodium 
citrate were collected. The blood was centrifuged at 580 g for 8 minutes at room temperature 
(PRGF® Model System Centrifuge IV®, Biotechnology Institute, San Antonio, Spain) as 
shown in figure 1. The 2 plasma fractions F1 and F2 were separated using a PRGF® Plasma 
Transfer Device supplied with the PRGF-Endoret® kit, care was taken not to include 
leukocytes (the buffy coat) when extracting F2. F1 was poured into a flat glass dish and 
placed in a Plasmatherm H Oven heated to 37°C for 15 minutes. The F1 clot underwent 
retraction to produce the F1 membrane and the liquid supernatant. F2 was then activated to 
induce fibrin clot formation. Before placement of the fibrin clot, PRGF® liquid supernatant 
was used to irrigate the socket, the F1 membrane was then applied to cover the surgical area 
and the socket margins were sutured. 
Outcome Measures 
Exposed alveolar bone, halitosis and dysgeusia were recorded as either present or absent and 
inflammation was assessed on a scale of 0-3 as detailed in table 1. To assess pain, patients 
were asked to complete a visual analogue score (VAS) training exercise so that they could 
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rate their pain using VAS on a 100mm line representing the spectrum of pain from no pain at 
all, to the worst pain imaginable. All these assessments at the initial treatment appointment 
were undertaken by the lead clinician prior to randomisation and treatment. 
The participants returned to the clinic after approximately 3 days (± day) for a review 
appointment, and again after approximately 7 days (± day) for review and suture removal. A 
second clinician, a qualified dentist, who was blinded in regards to the original treatment 
conducted the review appointments. At both review appointments the assessment of the 
clinical parameters pain, exposed alveolar bone, halitosis, dysgeusia and inflammation were 
repeated as described above. In addition, at each review appointment patients were asked to 
rate their swelling, bruising, bleeding and speed of healing by VAS. The lead clinician and 
second clinician were calibrated for halitosis scoring prior to the start of the study with a 
Kappa score of p=0.78 .If the patients needed to take analgesics after the placement of the 
dressing they were excluded from the study.   
Statistical Methods 
No previous clinical trial has compared the effect of PRGF® versus Alvogyl® in the 
management of AO. However, Alvogyl® had been examined for efficacy in the management 
of AO in a clinical trial by Kaya et al.24 The data obtained by Kaya et al.24 was used as a 
reference to calculate the statistical power in the current study. It was assumed that a sample 
size of 40 sockets (20 per each group), with a standard deviation of 2 and a decrease in pain 
of 6 points in the VAS would give a statistical power of 86.9%. Therefore, the aim was to 
recruit 20 sockets per group with the expectation that obtaining data from 17 per group would 
give a statistical power of 80% with the p value set at 0.05. 
For the analysis of statistical difference between continuous variables, a normality test 
(Shapiro Wilk test) was performed to determine whether the statistical test applied should be 
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parametric or non-parametric. For normally distributed continuous data Student t-test 
analyses were performed and for non normal distributions the Mann– Whitney U test was 
used. Log-linear analyses were performed where the relationship between more than two 
categorical variables was analysed. Where only two discrete categorical variables existed, 
Chi-squared analysis was performed to investigate whether the distributions of categorical 
variables differed from one another. 
The statistical significance was set at p-value ≤ 0.05. All the statistical analyses were 
performed using the SPSS v15.0 for Windows statistical software package (SPSS Inc., 
Chicago, IL, USA). Statisticians at Bristol University performed the statistical analysis. 
Results 
Recruitment 
38 patients, 20 males and 18 females, were enrolled in the study which ran from beginning of 
December 2014 to the end of February 2015. 33 patients presented with 1 AO socket, 4 
patients presented with 2 AO sockets and 1 patient presented with 3 AO sockets. In total 44 
AO sockets were treated on the trial. The average time between tooth extraction and the onset 
of AO was 2 days. 22 sockets were randomised to receive Alvogyl® and 22 sockets were 
randomised to receive PRGF®. The socket randomisation schedule resulted in four of the 
five patients with more than one AO, receiving one of each of the treatments. One patient 
failed to attend their first review appointment and another patient failed to attend their second 
review appointment. The data from the review appointments when the patients did attend was 
included in the statistical analysis. All patients responded to treatment after 7 days and were 
discharged. There were no complications or adverse events related to either treatment during 
the study period and all AO’s resolved by day 7 of the study. 
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Baseline 
There were no significant differences found between treatment groups with regards to age, 
race or gender (table 2). Similarly, no significant differences were identified comparing time 
period before the onset of AO symptoms the method of anaesthesia, tooth type extracted 
(incisor/premolar/molar), complexity of extraction or reason for extraction between groups. 
BPE results from all patients showed only 3 out of 38 patients had active periodontal disease. 
In addition, no significant differences were detected between the Alvogyl® and the PRGF® 
group with regards to the number of days elapsed prior to the first or second review 
appointment. However there were significantly more smokers randomised to the Alvogyl® 
treatment group. 
Outcomes 
In both treatment groups all clinical outcome measures improved during the course of the 
study (tables 3 and 4).  For patients treated with PRGF®, improvements were progressive for 
all measures, the best outcomes being observed at the second review appointment. By 
contrast, in the group treated with Alvogyl®, the amount of bone exposure and the number of 
patients with halitosis were lower at the first review than at the second review. Significant 
differences in several clinical outcomes were identified between the groups following 
treatment with Alvogyl® or PRGF®. By the second review appointment there was 
significantly less exposed bone and fewer patients with halitosis in the PRGF® group as 
compared to the Alvogyl® group. Similarly, at the second review clinical inflammation was 
significantly lower in patients in the PRGF® group compared to the Alvogyl® group. These 
differences were not significant at the initial treatment or first review appointment. Results 
for the 4 patients who had 2 or more AO and received both treatments supported these 
findings, with exposed bone scores and inflammation scores lower in the sockets treated with 
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PRGF® than in the sockets treated with Alvogyl®. No significant differences between the 
groups for dysgeusia were observed at any appointment, although for this measure, 2 of the 4 
patients receiving both treatments reported dysgeusia in the socket treated with PRGF® only. 
For both treatment groups, patient reported pain outcomes as scored by VAS improved 
progressively from screening to the second review appointment. Similarly, patient reported 
QoL outcomes as scored by VAS (speed of healing, swelling, bleeding and bruising) 
improved from the review appointment at 3 days to the review appointment at 7 days (table 
4). No significant differences between treatment groups for any patient reported QoL 
measurement were detected between groups at either review appointment. 
Significantly more smokers were randomised to the Alvogyl® group than to the PRGF® 
group. As a result of the differences in smoking status between groups, the results were first 
analysed including smokers as presented above, and secondly excluding smokers. The results 
differed in just one outcome measure when smokers were excluded, patient reported bleeding 
scores being significantly higher at the second review in the Alvogyl® group (p<0.05) as 
compared to the PRGF® group. Consequently, the data including smokers is presented. 
Discussion 
The purpose of this study was to compare the efficacy of PRGF® with the positive control 
Alvogyl® for the treatment of AO using pain, exposed bone, inflammation, halitosis, 
dysgeusia and quality of life as outcome measures. As patients who seek treatment for AO 
are in severe pain,3 no negative control was used in this trial as it was deemed unethical to 
leave patients with an untreated pain condition during the investigation. 
This study demonstrated that there was significantly less exposed bone at the second review 
in the PRGF® group compared to the Alvogyl® group, with similar results obtained whether 
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smokers were included or not. These results suggest that PRGF® caused less inflammation 
than Alvogel® resulting in improved healing and better bone coverage over the course of the 
study with PFRG®. Alternatively Alvogyl® may have been lost from the socket more easily 
than PRGF®. The data collected supports both theories, firstly greater bone exposure was 
observed in the Alvogyl® group at the second review as compared to the first review 
appointment. Secondly, analysing the inflammation data confirmed that there was 
significantly more inflammation in the Alvogyl® group at the second review than the first, 
suggesting that this may have been a factor in the reduced healing observed. As there was no 
untreated control group, whether this difference was due to PRGF® suppressing 
inflammation or Alvogyl® promoting it cannot be determined. Other studies have reported 
faster epithelialisation when using PRGF® of AO in extraction sockets,11, 19, 21 therefore it is 
possible that the improved bone coverage observed in the PRGF® group in this trial was a 
result of faster epithelialisation. The positive findings for PRGF® with respect to healing also 
lend support to those studies that have demonstrated that it appears to reduce the incidence of 
AO if applied following extraction. 19, 20 
Considering Alvogyl® is widely used as a dressing to treat AO, relatively few studies have 
investigated soft tissue healing following placement of Alvogyl® in post-extraction or AO 
sockets.  However, in a randomised controlled trial (RCT) that compared the efficacy of 
Alvogyl®, SaliCept Patch®, low-level laser therapy and no treatment controls in the 
management of AO it was demonstrated that exposed bone present at 3 days and 7 days 
following treatment was 34.6% and 3.8% respectively.24 Similarly, in a double blind RCT 
comparing Neocone®, Alvogyl® and zinc oxide eugenol packing for the treatment of AO it 
was demonstrated that in the Alvogyl® group the percentage of patients with exposed bone at 
3 days and 7 days were 52.65% and 10.52% respectively.25 In contrast to these studies, in the 
present study the levels of exposed bone in the Alvogyl® group increased between the first 
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and second review from 9.1 to 22.7%. In the study by Kaya et al.,24 the curettage, irrigation 
and dressing placement was repeated at 3 days and in the study by Faizel et al.25 it was 
replaced if necessary, when pain was persistent. In the present study the dressing was sutured 
in place which might have aided retention of the dressing. Dressings were not replaced at 3 
days reflecting normal practice where they are only changed if pain is persistent. 
In the current study significantly reduced inflammation was observed by the second review in 
the PRGF® group as compared to the Alvogyl® group, reduced inflammation was also 
observed in the PRGF® as compared to Alvogyl® sites in 3 out of the 4 participants who 
received both treatments at both review appointments. The only other study investigating 
PRGF® for the healing of AO sockets used PRGF® soaked gelatin sponge, eugenol and no 
treatment controls. This study also demonstrated significantly better soft tissue healing with 
PRGF® at 7 days,21 while, in a study which examined the healing of extraction sockets, 
significantly reduced swelling up to 7 days was observed in PRGF® treated as compared to 
control sites. This study also examined the levels of inflammatory molecules and concluded 
that while PRGF® induced both pro-and anti-inflammatory moleclues, the anti-inflammatory 
cytokines could inhibit the pro-inflammatory activities and promote healing.26 It is possible, 
therefore that the significantly lower level of inflammation observed by the PRGF® group as 
compared to the Alvogyl® group in the present study was due to an anti-inflammatory effect 
of PRGF rather than an inflammatory effect of Alvogyl®.  
It is widely agreed that AO is often accompanied by halitosis (oral malodour) which occurs 
as a result of collection of food debris and colonisation of anaerobic bacteria that produce 
volatile sulphur compounds,27 with studies reporting an incidence of between 33.3-76%.24, 28 
In the present study halitosis reduced by approximately 10% in both treatment groups by the 
first review, however, by the second review the percentage increased in the Alvogyl® group 
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but continued to decrease in the PRGF® group resulting in a significant difference between 
them. The debridement and irrigation of AO sockets, together with the placement of a 
dressing/barrier to food debris alone may be enough to improve halitosis immediately after 
surgery. At the later timepoint the significant difference may reflect the improved bone 
coverage in the PRGF® group, as compared to the Alvogyl® group, resulting in a reduced 
potential for food and debris packing. Alternatively, the reduction in halitosis scores could be 
due to the antimicrobial effect of PRGF® being greater than that of Alvogyl®. PRGF® has 
been shown to have antibacterial effects on Staphylococcus aureus and Staphylococcus 
epidermidis strains,13, 14 effects that may be mediated by the platelets which have been shown 
to have many functions in the antimicrobial host defence systems.29 By contrast, Alvogyl® 
contains the antiseptic iodoform which has been shown to have an antibacterial effect on 
several strains of oral bacteria.30 In the present study the increase in the numbers of patients 
with halitosis in the Alvogyl® group could reflect a decline in antimicrobial effects of the 
dressing, but perhaps also may reflect the potential that there was an increased accumulation 
of oral debris and bacteria due to dressing loss. The data obtained in the present study is in 
contrast to the findings of Kaya et al.24 who observed a progressive decline in halitosis over 7 
days following treatment with Alvogyl®. However, as indicated above, curettage and 
irrigation of the AO sockets was repeated at 3 days in the study by Kaya et al.,24 and bone 
coverage increased progressively.  
Halitosis is considered an important outcome measure for AO treatment, however measuring 
halitosis is clinically difficult. In the present study organoleptic assessment was used to detect 
halitosis. Although organoleptic testing is the gold standard for detecting the presence of 
halitosis,31 it is subjective can be a source of inter-examiner bias. In order to reduce bias in 
this investigation, both examiners were calibrated in detecting and recording halitosis at the 
beginning of the study.  
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In the present study the VAS scale which has been shown to be accurate for recording oral 
pain32, 33 was used to measure pain as well as patient perception of the quality of life 
measures of bleeding, swelling, speed of healing and bruising. Pain scores reduced 
progressively for both Alvogyl® and PRGF® treatment groups throughout the study with no 
significant differences between treatment groups. Alvogyl® contains the analgesics 
butamben and eugenol and has been shown to effectively reduce AO pain in a number of 
studies.25, 34, 35 By contrast, PRGF® does not contain analgesic constituents however, in a 
split-mouth RCT, PRGF® improved postoperative pain following tooth extraction as 
compared to placebo control and it was suggested this was a consequence of improved 
healing due to the release of growth factors and clot stability.20 Furthermore, platelet 
concentrates have shown to be effective at reducing inflammation36 and as pain is a symptom 
of inflammation, eradicating inflammation leads to a reduction in pain severity. It is therefore 
possible that the anti-inflammatory properties of PRGF® contributed to reduced 
postoperative pain in this trial.  
Dysgeusia is also caused by impaction of food debris and the accumulation of anaerobic 
bacteria. All patients within this study complained of dysgeusia at the screening appointment, 
and although there was a reduction in reporting of dysgeusia in both groups throughout the 
study, there was no significant difference between groups. In a study where platelet-rich 
plasma (cPRP) was used to treat extraction sockets there was also a positive effect on 
dysgeusia as compared to no-treatment controls.37 Taken together this data suggests that 
dressing of extraction sockets may be beneficial in reducing dysgeusia, and this may be a 
result of the dressing material reducing the extent of debris accumulation and resultant 
bacterial proliferation.  
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Interestingly, although clinical signs of increased bone coverage, resolution of inflammation 
and halitosis were significantly better in the PRGF® group compared to the Alvogyl® group, 
patients’ perception of swelling, bleeding, bruising and speed of healing was similar between 
groups, with all measures improving from day 3 to day 7. It is possible that pain reduction is 
the predominant clinical sign that patients’ associate with healing which could explain why 
pain scores correlated more closely with the other patient reported outcomes than with the 
clinician reported data.  Patient reported outcomes, while difficult to measure, are important 
as ultimately it is the patient who must be satisfied with the treatment outcome. 
As with all studies, certain limitations were recognised in the methodology of this 
investigation which may have had an influence on the overall results. Analysis of the 
randomisation revealed more smokers were randomised to the Alvogyl® group than the 
PRGF® group, therefore results were analysed both including and excluding smokers. 
Interestingly the results were similar whether smokers were included or not. This finding was 
somewhat surprising as in periodontal disease smoking has been shown compromise healing 
following treatment38, however to date there little literature regarding the effect of smoking 
on the healing of dry socket and this warrants further investigation.    
No significant differences were identified comparing method of anesthesia, tooth type 
extracted, complexity or reasons for of extraction in the two groups. These are interesting 
findings as this is not the case reviewing the literature. Further, periodontal examination 
results showed only 3 out of 38 patients had active periodontal disease, which again is as 
odds with literature.  One can argue the number of case in this study are low however, it is of 
particular interest that the cases of AO presenting were rarely smokers and had minimal 
periodontal disease and generally good oral health. This is worthy of further research as it 
contrasts sharply with the traditional literature. 
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In Conclusion, the results of this study suggest that PRGF® predictably treats alveolar 
osteitis following tooth extraction compared to standard UK guidance and protocols. PRGF® 
appears to be more beneficial than Alvogyl® for the treatment of alveolar osteitis with 
regards to reducing exposed bone, inflammation and halitosis. PRGF® and Alvogyl® are 
equally effective at reducing postoperative pain following treatment of alveolar osteitis and 
no difference in patients’ measurable quality of life parameters could be distinguished. PRGF 
could be used as an alterative treatment for AO and specifically for cases of iodine allergy. 
To confirm these findings, further evaluation of the efficacy of PRGF® over a longer time 
period with more patients is required together with cost, time and patient quality of life 
implications to confirm whether the use of PRGF® could be introduced as the new standard 
guidance. 
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Table 1: Assessment of Inflammation at treatment and review appointments 
Clinical 
Parameter 
Method of assessment 
Inflammation 0  Absence 
1 – Slight swelling and hardness 
2 – Fascial planes blurring without affectation of nasolabial folds or eyes 
3 – Fascial planes blurring with affectation of nasolabial folds and eyes 
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Table 2: Baseline demographic and smoking status data for Alvogyl® and PRGF® groups. 
Baseline Data All Alvogyl® 
(n=22) 
PRGF® 
(n=22) 
P < 0.05 
Age (years) 40.7 ± 17.3 39.4 ± 16.9 41.1 ± 17.9 NSa 
Gender    
NSb Female 20 9 11 
Male 24 13 11 
Race    
NSc 
Caucasian 39 20 19 
Black 3 2 1 
Asian 2 0 2 
Hispanic 1 0 1 
Smoking status    
p<0.05b Smokers 13  11  2  
Non Smokers 31 11 20 
Smoking (years) 26.3 ± 15.5 12.8 ± 17.3 2.7 ± 9.4 p<0.05d 
Cigarettes/day 11.5 ± 5.7 5.6 ± 6.8 1.1 ± 18.8 p<0.05d 
Onset of symptoms (days) 2 ± 1 2.1 ± 1.3 2.0 ± 1.7 NSd 
Type of anaesthesia for 
tooth extraction 
Local 
Sedation + Local 
General 
 
 
35 
7 
2 
 
 
18 
3 
1 
 
 
17 
4 
1 
NSc 
Tooth type    NSc 
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Anterior 
Premolar 
Molar 
3 1 2  
4 0 4 
37  21  16 
Reason for Extraction  
Caries (Unrestorable) 
Pericoronitis 
Impacted tooth 
Periapical periodontitis 
Abscess 
Irreversible pulpitis 
Pre-OMFS* surgery 
Unknown 
   
NSc 
17  8  9 
8 3  5  
5  3  2  
6 
4 
4 
1 
2  
3 
2  
1 
1 
1  
1 
1 
1 
0  
0 
Complexity of extraction 
Difficulty 1 
Difficulty 2 
Difficulty 3 
No radiograph available 
 
16 
10 
9 
7 
 
8 
6 
4 
5 
 
8 
4 
5 
2 
 
NSd 
Analysed using a: student t-test; b: chi-squared test; c: loglinear analysis and d: Mann-
Whitney test. NS = not significant 
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Table 3: Differences in clinical scores between Alvogyl® and PRGF® treatments.  
Clinical parameter Appointment 
Alvogyl® 
(n=22) 
PRGF® 
(n=22) 
p-value 
Inflammation  
clinical scoring (0-3) 
Screening 2.24 ± 0.5 2.52 ± 0.5 NS 
1st review 1.33 ± 0.7 0.95 ± 0.8 NS 
2nd review 1.19 ± 0.8 0.67 ± 0.7 p<0.05 
Exposed Bone 
(% of patients) 
(present/absent)  
Screening 100 100 NS 
1st review 9.1 9.1 NS 
2nd review 22.7 0 p<0.05 
Halitosis 
(% of patients) 
(present/absent) 
Screening 100 100 NS 
1st review 40.9 33.3 NS 
2nd review 42.9 9.1 p<0.05 
Dysgeusia 
(% of patients) 
(present/absent) 
Screening 100 100 NS 
1st review 68.2 47.6 NS 
2nd review 42.9 27.3 NS 
 
NS = not significant. 
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Table 4: Differences in quality of life parameters between Alvogyl® and PRGF® treatments 
as determined by VAS. 
 
Quality of Life 
Parameter 
VAS score (cm) 
Appointment 
Alvogyl® 
(n=22) 
PRGF® 
(n=22) 
p<value 
Pain 
Screening 6.6 ± 2.3 6.4 ± 1.8 NS 
1st review 4.3 ± 2.9 4.0 ± 2.7 NS 
2nd review 2.4 ± 2.6 2.0 ± 2.0 NS 
Swelling 
1st review 2.9 ± 2.7 2.3 ± 2.3 NS 
2nd review 1.8 ± 1.8 1.2 ± 1.7 NS 
Bleeding 
1st review 1.3 ± 1.7 0.9 ± 1.2 NS 
2nd review 0.7 ± 0.8 0.4 ± 0.6 NS 
Bruising 
1st review 1.5 ± 2.3 1.7 ± 2.4 NS 
2nd review 1.2 ± 1.7 1.3 ± 2.3 NS 
Healing 
1st review 5.4 ± 2.9 5.6 ± 2.1 NS 
2nd review 5.6 ± 2.9 6.7 ± 2.7 NS 
NS = not significant 
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Figure 1: Plasma fractions obtained after centrifugation of whole blood 
 
